What’s the difference between Wegovy and Saxenda for weight loss, and how are they prescribed in Europe?

Wegovy vs Saxenda explained: semaglutide vs liraglutide, dosing schedule, effectiveness, side effects, and medical eligibility criteria.

In this episode, we compare two GLP-1 receptor agonists approved for weight management and clarify how suitability is assessed during an online consultation in the EU.

You’ll learn:

• The active ingredients: semaglutide (Wegovy) vs liraglutide (Saxenda)

• Weekly vs daily injection schedules

• Differences in average weight reduction observed in clinical trials

• Common side effects such as nausea, vomiting, and gastrointestinal discomfort

• BMI thresholds and obesity-related conditions used in eligibility assessment

• Contraindications, including certain endocrine and gastrointestinal disorders

• Situations where a prescription request may be declined pending blood tests or specialist review

We explain how doctors assess BMI, comorbidities (such as type 2 diabetes or hypertension), medication history, and cardiovascular risk before recommending treatment. GLP-1 therapies require ongoing monitoring and are not suitable for everyone.

This episode reflects the clinical standards used by Mobi Doctor, where weight management consultations are reviewed by a registered physician in line with EU prescribing guidance.

Read the full guide and transcript here:

https://www.mobidoctor.eu/blog/wegovy-vs-saxenda-whats-the-difference-for-weight-loss